Compare ARK Genomic Revolution ETF (ARKG) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | BIL | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $44.55 | $91.77 |
52-Week Low | $24.02 | $91.27 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
